Literature DB >> 26672617

A new model of an arteriovenous fistula in chronic kidney disease in the mouse: beneficial effects of upregulated heme oxygenase-1.

Lu Kang1, Joseph P Grande2, Matthew L Hillestad3, Anthony J Croatt1, Michael A Barry4, Zvonimir S Katusic5, Karl A Nath6.   

Abstract

The arteriovenous fistula (AVF) is the preferred hemodialysis vascular access, but it is complicated by high failure rates and attendant morbidity. This study provides the first description of a murine AVF model that recapitulates two salient features of hemodialysis AVFs, namely, anastomosis of end-vein to side-artery to create the AVF and the presence of chronic kidney disease (CKD). CKD reduced AVF blood flow, observed as early as 3 days after AVF creation, and increased neointimal hyperplasia, venous wall thickness, thrombus formation, and vasculopathic gene expression in the AVF. These adverse effects of CKD could not be ascribed to preexisting alterations in blood pressure or vascular reactivity in this CKD model. In addition to vasculopathic genes, CKD induced potentially vasoprotective genes in the AVF such as heme oxygenase-1 (HO-1) and HO-2. To determine whether prior HO-1 upregulation may protect in this model, we upregulated HO-1 by adeno-associated viral gene delivery, achieving marked venous induction of the HO-1 protein and HO activity. Such HO-1 upregulation improved AVF blood flow and decreased venous wall thickness in the AVF. Finally, we demonstrate that the administration of carbon monoxide, a product of HO, acutely increased AVF blood flow. This study thus demonstrates: 1) the feasibility of a clinically relevant murine AVF model created in the presence of CKD and involving an end-vein to side-artery anastomosis; 2) the exacerbatory effect of CKD on clinically relevant features of this model; and 3) the beneficial effects in this model conferred by HO-1 upregulation by adeno-associated viral gene delivery.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  arteriovenous fistula; chronic kidney disease; heme oxygenase-1; murine model

Mesh:

Substances:

Year:  2015        PMID: 26672617      PMCID: PMC4796269          DOI: 10.1152/ajprenal.00288.2015

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  47 in total

1.  Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.

Authors:  Tanushree Banerjee; S Joseph Kim; Brad Astor; Tariq Shafi; Josef Coresh; Neil R Powe
Journal:  Am J Kidney Dis       Date:  2014-09-27       Impact factor: 8.860

2.  Timing of arteriovenous fistula placement: keeping it in perspective.

Authors:  Bradley S Dixon
Journal:  J Am Soc Nephrol       Date:  2014-08-28       Impact factor: 10.121

3.  Dialysis: optimal timing of arteriovenous fistula placement in elderly patients.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2014-09-16       Impact factor: 28.314

4.  Longitudinal assessment of hemodynamic endpoints in predicting arteriovenous fistula maturation.

Authors:  Ehsan Rajabi-Jagahrgh; Mahesh K Krishnamoorthy; Prabir Roy-Chaudhury; Paul Succop; Yang Wang; Ann Choe; Rupak K Banerjee
Journal:  Semin Dial       Date:  2012-08-14       Impact factor: 3.455

5.  Blocking Notch in endothelial cells prevents arteriovenous fistula failure despite CKD.

Authors:  Yun Wang; Anlin Liang; Jinlong Luo; Ming Liang; Guofeng Han; William E Mitch; Jizhong Cheng
Journal:  J Am Soc Nephrol       Date:  2014-01-30       Impact factor: 10.121

6.  Vascular remodeling and intimal hyperplasia in a novel murine model of arteriovenous fistula failure.

Authors:  Chun-Yu Wong; Margreet R de Vries; Yang Wang; Joost R van der Vorst; Alexander L Vahrmeijer; Anton Jan van Zonneveld; Prabir Roy-Chaudhury; Ton J Rabelink; Paul H A Quax; Joris I Rotmans
Journal:  J Vasc Surg       Date:  2013-05-15       Impact factor: 4.268

7.  Arteriovenous fistula placement in the elderly: when is the optimal time?

Authors:  Tammy Hod; Bhanu K Patibandla; Yael Vin; Robert S Brown; Alexander S Goldfarb-Rumyantzev
Journal:  J Am Soc Nephrol       Date:  2014-08-28       Impact factor: 10.121

8.  Renal function, uraemia and early arteriovenous fistula failure.

Authors:  Emma Aitken; Andrew Jackson; Chia Kong; Paul Coats; David Kingsmore
Journal:  BMC Nephrol       Date:  2014-11-17       Impact factor: 2.388

Review 9.  Role of far infra-red therapy in dialysis arterio-venous fistula maturation and survival: systematic review and meta-analysis.

Authors:  Khalid Bashar; Donagh Healy; Leonard D Browne; Elrasheid A H Kheirelseid; Michael T Walsh; Mary Clarke-Moloney; Paul E Burke; Eamon G Kavanagh; Stewart Redmond Walsh
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

10.  Adventitial delivery of lentivirus-shRNA-ADAMTS-1 reduces venous stenosis formation in arteriovenous fistula.

Authors:  Evelyn C Nieves Torres; Binxia Yang; Bhaskar Roy; Rajiv Janardhanan; Akshaar Brahmbhatt; Ed Leof; Debabrata Mukhopadhyay; Sanjay Misra
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

View more
  22 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Moving Beyond the Assumed: Improving Fistula Success Rates.

Authors:  Jay B Wish; Sharon M Moe
Journal:  J Am Soc Nephrol       Date:  2017-07-21       Impact factor: 10.121

Review 3.  New Insights into Dialysis Vascular Access: Molecular Targets in Arteriovenous Fistula and Arteriovenous Graft Failure and Their Potential to Improve Vascular Access Outcomes.

Authors:  Timmy Lee; Sanjay Misra
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-11       Impact factor: 8.237

4.  Antithrombotic effects of heme-degrading and heme-binding proteins.

Authors:  Karl A Nath; Joseph P Grande; John D Belcher; Vesna D Garovic; Anthony J Croatt; Matthew L Hillestad; Michael A Barry; Meryl C Nath; Raymond F Regan; Gregory M Vercellotti
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-01-31       Impact factor: 4.733

5.  Predicting the Functionality and Form of a Dialysis Fistula.

Authors:  Karl A Nath; Zvonimir S Katusic
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

6.  Challenges in Developing New Therapies for Vascular Access Dysfunction.

Authors:  Karl A Nath; Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2017-09-11       Impact factor: 8.237

7.  Therapeutic Effect of Adipose Derived Mesenchymal Stem Cell Transplantation in Reducing Restenosis in a Murine Angioplasty Model.

Authors:  Chuanqi Cai; Sreenivasulu Kilari; Chenglei Zhao; Michael L Simeon; Avanish Misra; Yiqing Li; Andre J van Wijnen; Debabrata Mukhopadhyay; Sanjay Misra
Journal:  J Am Soc Nephrol       Date:  2020-06-25       Impact factor: 10.121

8.  The murine dialysis fistula model exhibits a senescence phenotype: pathobiological mechanisms and therapeutic potential.

Authors:  Karl A Nath; Daniel R O'Brien; Anthony J Croatt; Joseph P Grande; Allan W Ackerman; Meryl C Nath; Satsuki Yamada; Andre Terzic; Tamara Tchkonia; James L Kirkland; Zvonimir S Katusic
Journal:  Am J Physiol Renal Physiol       Date:  2018-07-18

Review 9.  Vascular Access for Hemodialysis Patients: New Data Should Guide Decision Making.

Authors:  Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-11       Impact factor: 8.237

10.  Abnormalities of vascular histology and collagen fiber configuration in patients with advanced chronic kidney disease.

Authors:  Michael Allon; Silvio H Litovsky; Jason Chieh Sheng Tey; Chad A Sundberg; Yingying Zhang; Zhen Chen; Yun Fang; Alfred K Cheung; Yan-Ting Shiu
Journal:  J Vasc Access       Date:  2018-05-09       Impact factor: 2.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.